OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

EMERYVILLE, Calif.–(BUSINESS WIRE)—- $OABI #Antibody–OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new platform license agreements in the first quarter, bringing our total active partners to 80, net of attrition,” said Matt Foehr, Chief Executive Officer of O
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks